Stocks›Healthcare›VERA

VERA

Vera Therapeutics, Inc.

NasdaqResearch view

Healthcare · Pharmaceutical Preparations

Price history

Chart: TradingView’s own feed · page prices: 1D EOD

🔒 Click to interact · scroll moves the page

The record

LAST 90 DAYS · 1D EOD

1 story has a settled receipt so far (1 on the Wire). The record starts speaking at three.

Jul 8Guggenheim raises Vera Therapeutics stock price target on FDA approvalInvesting.com−1.23%1D

Reaction = the first close after the story against the close before it. Prior-session closes only; not a call, not advice.

Snapshot

SEC EDGAR

SectorHealthcare

Income—

Sales—

Book/sh—

Cash/sh—

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio—

Current Ratio—

Debt/Eq—

EPS (ttm)—

EPS this Y—

EPS past 3/5Y—

Sales past 3/5Y—

EPS Y/Y TTM—

Sales Y/Y TTM—

Shs Outstand—

ROA—

ROE—

ROIC—

Gross Margin—

Oper. Margin—

Profit Margin—

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue & Earnings — fiscal year

Revenue history unavailable.

Follow the news. Track the move.

VERA story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

VERA direct/Earnings

Sep 15

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

Vera Therapeutics said TRUTAKNA stabilized eGFR and prevented kidney-disease progression through two years in the final ORIGIN 3 analysis for IgA nephropathy. The result strengthens the drug’s long-term efficacy case, but the announcement does not disclose the numerical efficacy results or the next regulatory milestone.

Price history unavailable

GlobeNewswire · 1h ago

View both sides →

VERA direct/Earnings

Jul 8

Guggenheim raises Vera Therapeutics stock price target on FDA approval

Guggenheim has increased its price target for Vera Therapeutics (NASDAQ: VERA) following the FDA approval of one of its key drugs. This upgrade signals a positive outlook for the company's future revenue potential and market position.

Price history unavailable

Investing.com · 68d ago

View both sides →

Follow the news. Track the move.